Pipeline

Anti-Gram-negative programs

PathogenHTS – HitIDH2LLOPreclin. dev.Clinical dev.
Acinetobacter baumannii
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Other pathogens

Anti-Acinetobacter baumannii development program

Using the proprietary discovery engine, PasNas, ABAC Therapeutics has generated a series of promising molecules that show good antibacterial activity against a panel of multi-drug resistant bugs and clinical isolates of Acinetobacter baumannii, and have an improved safety and efficacy profile in preclinical models, together with a novel mechanism of action.

Anti-Escherichia coli and anti-Klebsiella pneumoniae programs

Pathogen-specific compounds active against Escherichia coli and Klebsiella pneumoniae are being evaluated to select new leads.

The compounds generated in this programs demonstrate no cross-resistance with current antibiotics and therefore retain activity against strains harboring resistance mechanisms that inactivate many other marketed antibiotics.